ArticleGastroenterology research and practice2012
Liver disorders in inflammatory bowel disease.
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 66 citations in OpenAlex.
- Trial
- Strain-specific responses to dextran sulfate sodium-induced ulcerative colitis in BALB/c and C57BL/6 mice: Comparative analysis of local versus extra-intestinal manifestations.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Therapeutic Effects ofNutrients · 2024Article
- Methionine-choline deficient diet deteriorates DSS-induced murine colitis through disturbance of gut microbes and infiltration of macrophages.Acta pharmacologica Sinica · 2024Article
- Granulomatous hepatitis with Crohn's disease: a case report.Clinical journal of gastroenterology · 2024Article
- Effective enhancement of the immunomodulatory capacity of canine adipose-derived mesenchymal stromal cells on colitis by priming with colon tissue from mice with colitis.Frontiers in veterinary science · 2024Article
- The Role of Gut Microbiome-Derived Short-Chain Fatty Acid Butyrate in Hepatobiliary Diseases.The American journal of pathology · 2023Review
- Polysaccharide fromInternational journal of molecular sciences · 2022Article
- Article
- Inflammatory bowel disease biomarkers.Medicinal research reviews · 2022Review
- Effects of β-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice.European journal of nutrition · 2022Article
- Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.Frontiers in immunology · 2022Review
- Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration.Frontiers in immunology · 2022Article
- Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.Journal of clinical medicine · 2021Article
- Article
- Metabolic Profiling by UPLC-Orbitrap-MS/MS of Liver from C57BL/6 Mice with DSS-Induced Inflammatory Bowel Disease.Mediators of inflammation · 2020Article
- Leukotrienes in Tumor-Associated Inflammation.Frontiers in pharmacology · 2020Review
- Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab.Diseases (Basel, Switzerland) · 2019Article
- Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Journal of clinical medicine research · 2019Review
- Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.Gastroenterology research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disorders of the hepatobiliary system are relatively common extraintestinal manifestations of inflammatory bowel disease (IBD). These disorders are sometimes due to a shared pathogenesis with IBD as seen in primary sclerosing cholangitis (PSC) and small-duct primary sclerosing cholangitis (small-duct PSC). There are also hepatobiliary manifestations such as cholelithiasis and portal vein thrombosis that occur due to the effects of chronic inflammation and the severity of bowel disease. Lastly, medications used in IBD such as sulfasalazine, thiopurines, and methotrexate can adversely affect the liver. It is important to be cognizant of these disorders as some do have serious long-term consequences. The management of these disorders often requires the expertise of multidisciplinary teams to achieve the best outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.